How to Help Your Patients Find Epclusa In Stock: A Provider's Guide

Prescribing Epclusa is only the first step. For many hepatitis C patients in 2026, the real challenge begins when they try to fill the prescription. As a provider, you play a critical role in bridging the gap between a written prescription and a patient actually starting treatment. This guide gives you actionable strategies to help your patients navigate the access barriers that commonly delay or derail Epclusa treatment.

Why Your Patients Can't Find Epclusa

Epclusa is not in a formal FDA shortage — but patients encounter significant access friction due to:

• Prior authorization requirements across nearly all payers (commercial, Medicare Part D, Medicaid)
• Specialty pharmacy routing — many plans only cover Epclusa through specific specialty pharmacies
• Retail pharmacy reluctance to stock ~$24,000+ per unit without a confirmed order
• Step therapy requirements (Mavyret first) at some commercial payers
• Patient confusion about insurance processes and pharmacy options

Strategy 1: Submit a Complete Prior Authorization Upfront

The single most impactful thing you can do is submit a thorough PA request the first time. Incomplete submissions are the leading cause of PA delays. Include:

• Positive HCV RNA (quantitative) and HCV genotype
• Fibrosis staging (FIB-4 score, FibroScan, or biopsy)
• Prior treatment history
• HBsAg and anti-HBc test results (per boxed warning requirement)
• Clinical rationale if patient has decompensated cirrhosis (Epclusa + ribavirin is the only appropriate DAA option)

Strategy 2: Identify the Right Pharmacy Before You Prescribe

Ask your staff to verify the patient's plan formulary and specialty pharmacy requirements before sending the prescription. Sending a prescription to a retail pharmacy that the plan doesn't cover for specialty drugs means the patient will face a denial at the counter — and may not understand why.

Major specialty pharmacy partners to consider:

• CVS Specialty — commonly in-network for commercial and Medicare plans
• Accredo (Express Scripts) — preferred for many PBM-administered plans
• Optum Specialty Pharmacy — preferred for UnitedHealth plans
• Walgreens Specialty — broad network coverage

Strategy 3: Use Medfinder to Locate Stock for Your Patients

For patients who need help finding a pharmacy that currently has Epclusa available, medfinder for Providers is a useful tool. medfinder contacts nearby pharmacies on behalf of the patient to find which ones can fill the prescription. You can recommend this resource directly to patients who are calling multiple pharmacies without success.

Strategy 4: Appeal PA Denials Promptly and Effectively

If a PA is denied, file an appeal immediately. Common grounds for successful appeal include:

• Decompensated cirrhosis (clinically, Mavyret is not an option — document Child-Pugh score)
• Prior treatment failure with the payer's preferred alternative
• Drug interaction with the preferred alternative that makes it unsafe for this patient
• AASLD/IDSA guideline citation supporting Epclusa for this patient's specific situation

Strategy 5: Connect Patients with Gilead's Support Path

Gilead's Support Path program (MySupportPath.com, 1-855-769-7284, Mon–Fri 9 AM–8 PM ET) offers:

• PA assistance and appeals support for commercially insured patients
• Co-pay assistance card: as low as $5/month for eligible commercially insured patients
• Patient Assistance Program: free medication for uninsured or underinsured patients who meet income requirements
• Specialty pharmacy identification and referral

Strategy 6: Consider the Authorized Generic

For cash-paying patients, consider prescribing the authorized generic (sofosbuvir/velpatasvir by Asegua Therapeutics). The list price is approximately $6,728 for 28 tablets — significantly lower than the brand's $24,350. The identical active ingredients ensure the same clinical outcome. Ask the patient to verify which version their pharmacy carries.

Key Message for Your Care Team

Epclusa access in 2026 requires proactive team-based support. The prescriber, your front office, and your medical assistant all have a role in making sure the patient actually starts treatment. For a deeper clinical review, see our provider guide on Epclusa access barriers in 2026.